Protective effects of Lacticaseibacillus rhamnosus on isoprenaline-induced myocardial infarction in rats

Area of Science:

• Cardiology
• Microbiology
• Pharmacology

Background:

• Myocardial infarction (MI) is a leading cause of mortality worldwide, often leading to heart failure and fibrosis.
• Gut microbiota dysbiosis is increasingly linked to cardiovascular diseases, including atherosclerosis.
• Lacticaseibacillus rhamnosus GG possesses known anti-inflammatory and antioxidant properties.

Purpose of the Study:

• To investigate the cardioprotective effects of Lacticaseibacillus rhamnosus GG against isoprenaline-induced myocardial infarction in a rat model.
• To evaluate the impact of L. rhamnosus GG on key biomarkers of cardiac damage and inflammation.

Main Methods:

• Rats were divided into control, isoprenaline (ISO)-induced MI, L. rhamnosus GG treated, and combined ISO + L. rhamnosus GG groups.
• Subcutaneous ISO injections were administered to induce MI on days 27 and 28 of a 28-day treatment period.
• Cardiac damage markers (creatine kinase-MB, troponin-I), inflammatory cytokines (TNF-α, IL-10), CRP, and ECG parameters were assessed.

Main Results:

• L. rhamnosus GG administration significantly reduced elevated levels of troponin-I, creatine kinase-MB, CRP, and TNF-α in ISO-treated rats.
• The probiotic increased beneficial interleukin-10 levels compared to the ISO group.
• ECG analysis showed that L. rhamnosus GG mitigated ST-segment elevation and improved R wave amplitude reduction caused by ISO.

Conclusions:

• Lacticaseibacillus rhamnosus GG demonstrates significant cardioprotective effects in an experimental model of myocardial infarction.
• The probiotic's benefits are associated with the modulation of cardiac damage markers and inflammatory responses.
• L. rhamnosus GG holds potential as a therapeutic agent for managing myocardial infarction and related cardiovascular complications.